Status:

RECRUITING

AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip

Lead Sponsor:

McMaster University

Collaborating Sponsors:

Geistlich Pharma AG

Conditions:

Hip Arthroscopy

Articular Cartilage Defect

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This is a pilot multi-centre RCT of 40 patients (ages 18-55 years, inclusive) undergoing primary hip arthroscopy with a focal articular cartilage defect of the acetabulum to compare the effect of usin...

Eligibility Criteria

Inclusion

  • All patients aged 18-55 years
  • Hip pain lasting 6 months or more with no relief from documented non-operative modalities
  • Focal articular cartilage defects of the acetabulum on MRI, confirmed to be full thickness (International Cartilage Regeneration and Joint Preservation Society (ICRS) grade 3 or 4) during arthroscopic examination
  • Focal acetabular articular cartilage lesions measuring between 3 cm2 and 25 cm2 on MRI and confirmed on arthroscopic examination
  • Patient agrees to participate in the study-specific postoperative rehabilitation protocol
  • Patient can speak, read, and understand the language of the site
  • Patient has provided informed consent

Exclusion

  • Cartilage defects of the femoral head
  • Previous surgery on the study hip
  • Traumatic chondral injury of the hip from a single event
  • Presence of advanced osteoarthritis (Tonnis grade 3) or any other acute or chronic inflammatory joint disease
  • Known hypersensitivity or allergy to porcine collagen
  • Acute or chronic infection at the surgical site
  • Evidence of hip dysplasia (i.e., lateral centre edge angle \< 20˚)
  • Evidence of acetabular over coverage such as coxa profunda or coxa protrusion
  • Immunosuppressive or anti-proliferative medication use
  • Chronic pain syndromes
  • Significant medical co-morbidities (requiring assistance for activities of daily living (ADLs))
  • History of paediatric hip disease
  • Uncontrolled diabetes
  • Contraindications to MRI imaging (e.g. claustrophobia)
  • Patient is involved in ongoing legal or workplace claims
  • Patient is incarcerated
  • Patient is pregnant or breastfeeding
  • Patient who will likely have problems, in the judgement of the investigator, with maintaining follow-up
  • Any other reason(s) the investigator feels is relevant for excluding the patient

Key Trial Info

Start Date :

March 13 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2027

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT05402072

Start Date

March 13 2023

End Date

January 1 2027

Last Update

September 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

McMaster University

Hamilton, Ontario, Canada, L8N3Z5